AT13148 NEW
| Price | $41 | $57 | $116 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: AT13148 | CAS No.: 1056901-62-2 |
| Purity: ≥95% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | AT13148 |
| Description | AT13148 is an oral-active and ATP-competitive, multi-AGC kinase inhibitor for Akt1/2/3, p70S6K, PKA, and ROCKI/II. |
| Cell Research | Cytotoxicity is determined using a 72 h Alamar Blue assay or a 96 h SRB assay. (Only for Reference) |
| Kinase Assay | In vitro kinase assays: AT13148 is assayed against 40 kinases and the percentage inhibition at 10 μM of AT13148 is determined. Individual IC50 values are measured for selected kinases using ATP concentrations equivalent to the Km for each enzyme. |
| In vitro | In PTEN-deficient MES-SA cells, AT13148 was able to inhibit AKT and p70S6K signaling. In cancer cell lines with aberrant PI3K-AKT-mTOR or RAS-RAF pathways (GI50=1.5-3.8 μM), AT13148 was able to inhibit multiple AGC kinases, thereby suppressing cancer cell proliferation. |
| In vivo | In PTEN-deficient MES-SA cells, AT13148 was able to inhibit AKT and p70S6K signaling. In cancer cell lines with aberrant PI3K-AKT-mTOR or RAS-RAF pathways (GI50=1.5-3.8 μM), AT13148 was able to inhibit multiple AGC kinases, thereby suppressing cancer cell proliferation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 58 mg/mL (184.8 mM) |
| Keywords | inhibit | Protein kinase B | S6K | PKB | AT-13148 | ROK | Protein kinase A | Rho-associated protein kinase | Akt | PKA | AT13148 | Rho-associated kinase | Ribosomal S6 Kinase (RSK) | Rho-kinase | ROCK | Inhibitor | AT 13148 |
| Inhibitors Related | Ethyl gallate | Acefylline | Staurosporine | RKI-1447 | Artemisinin | Honokiol | Y-27632 dihydrochloride | 2,3-Butanediol | Y-27632 | Thiazovivin | Sodium salicylate | JAK1/2/3 Inhibitor 1 |
| Related Compound Libraries | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | TGF-beta/Smad Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY